Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.

Teddy Rosenbluth
Author: Teddy Rosenbluth

Written by

Teddy Rosenbluth

in

Cassava Sciences Inc, Clinical Trials, Decisions and Verdicts, Falsification of Data, Regulation and Deregulation of Industry, Research, Securities and Commodities Violations, simufilam
←At the Brooklyn Academy, Musical Journeys Through Minefields
EV Projects to Get $13 Billion in Federal Loans→

More posts

  • Protesters, leaders push back against DHS over Newark detention facility conditions

  • Goldman and Lander spar hard over Israel

  • Snowflake climbs after Q1 results top expectations, guidance gets a boost

  • Synopsys drops despite better than expected Q2 results, big boost to full-year guidance

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube